COVID-19：露RDIF,アビガン（ファビピラビル）有望な兆候示す：Kirill Dmitriev said（動画）：
Russia claims promising signs in early trials of antiviral drug favipiravir Wednesday：
俄罗斯在抗病毒药物favipiravir的早期试验中声称有希望的迹象，星期三，
COVID-19：
2020年5月13日10時24分
モスクワ（ロイター）
COVID-19治療薬/ファビピラビルが、ロシアの初期臨床試験で、有望な結果を示しました、
露RDIF：
このプロジェクトに、1億5000万ルーブル（200万ドル）の資金を出資しています。
RDIF：キリル・ドミトリエフ氏
40人の新型コロナウイルス患者に、日本で開発のアビガン（ファビピラビル）の錠剤を、服用させました。
アビガン（ファビピラビル）：投与の結果
- 新型コロナウイルス患者40人の内、
- 60％の患者が、ウイルス検査で5日以内に陰性となり、
- アビガン服用で、新型コロナウイルス症状の回復時間が、半分に短縮しました。
Drugmakers
are rushing to develop treatments and vaccines for the highly contagious coronavirus that has killed over 290,000 people worldwide,
infected more than 4.2 million and ravaged economies globally.
Avigan, known generically as favipiravir,
was developed in the late 1990s by a company later bought by Fujifilm as it moved into healthcare.
The drug works by short-circuiting the reproduction mechanism of certain RNA viruses such as influenza.
Favipiravir
is also undergoing trials in India by Glenmark Pharmaceuticals Ltd.
Russia,
which has the second-highest number of coronavirus cases behind the United States,
is also testing vaccine prototypes on animals, while the RDIF has diverted funds to produce more tests domestically.
“This will reduce the burden on medical centres and, according to our estimates, will also reduce the number of epidemiologically dangerous patients by about 50%,”
Dmitriev said, referring to a course of favipiravir treatment.
The clinical trial of 330 patients infected with the coronavirus should be finished by the end of May,
said Andrei Ivashchenko, a professor at the Russian Academy of Sciences and chairman of the board of directors at ChemRar, the company conducting the trials.
“ChemRar’s existing production facilities…
will allow us to produce tens of thousands of treatment programmes per month, which we estimate and hope will be enough for the Russian Federation as a minimum,” said Ivashchenko.
He said early tests showed that
there were minimal side effects, although he added that more testing was needed before pregnant women could use it. The drug Avigan in Japan was found to cause birth defects.
Ivashchenko also said
there was not enough data to say how effective the treatment would be for severely ill patients.
The World Health Organisation (WHO)
sets out a four-phase overview of how clinical trials work. The trials underway in Russia would fall into the first phase of that framework.
“Phase I studies usually test new drugs for the first time in a small group of people to evaluate a safe dosage range and identify side effects,” the WHO says on its website.
News | WIN 98.5